36
Participants
Start Date
March 31, 2013
Primary Completion Date
October 9, 2019
Study Completion Date
October 31, 2032
BPX-501 dose 1
Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
Rimiducid
Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
BPX-501 dose 2
Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
BPX-501 dose 3
Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
BPX-501 dose 4
Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
SCT
all subjects will receive an alpha beta depleted donor transplant as part of treatment
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
Emory University Winship Cancer Institute, Atlanta
University Hospitals of Cleveland, Cleveland
Baylor Sammons Cancer Center, Dallas
UT Southwestern Medical Center, Dallas
Oregon Health & Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
Lead Sponsor
Bellicum Pharmaceuticals
INDUSTRY